Tasly drug approved for acute ischemic stroke treatment

Tasly Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Tasly Biological Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration. This approval adds a new indication for its biological innovative drug, Recombinant Human Pro-Urokinase for Injection (Puyoukang), for the thrombolytic treatment of acute ischemic stroke. Puyoukang is an independently developed Class 1 biological innovative drug and this marks its second approved indication in China.

Acute ischemic stroke (AIS) is a common type of stroke with high incidence, recurrence, disability, and mortality rates. The new indication expands the target patient population for Puyoukang and is expected to enhance Tasly’s product line in the neurological/psychiatric field, boosting its market competitiveness.

The cumulative research and development investment for Puyoukang’s acute ischemic stroke thrombolytic treatment indication totals CNY 32,932.80. The company will proceed with related work, while acknowledging potential risks from national policies and market conditions affecting production and sales.